EntryPoint Capital’s Pacira BioSciences PCRX Stock Holding History

EntryPoint Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,268	Closed	-$481K	–	919
2026 Q1	$481K	Sell	21,268 -4,914	-19%	-$109K	0.14%	267
2025 Q4	$678K	Buy	+26,182	New	+$623K	0.26%	81
2025 Q1	–	Sell	-23,021	Closed	-$434K	–	886
2024 Q4	$434K	Buy	23,021 +7,062	+44%	+$124K	0.18%	166
2024 Q3	$240K	Buy	15,959 +1,923	+14%	+$32.9K	0.14%	360
2024 Q2	$402K	Buy	14,036 +5,701	+68%	+$162K	0.19%	80
2024 Q1	$244K	Buy	8,335 +2,629	+46%	+$80.8K	0.22%	55
2023 Q4	$193K	Buy	+5,706	New	+$167K	0.18%	106

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EntryPoint Capital's PCRX Position: Q2 2026 in Review

EntryPoint Capital sold out of Pacira BioSciences (PCRX) in Q2 2026, closing a stake of 21,268 shares — an estimated $481K sold.

EntryPoint Capital first reported a position in PCRX in Q4 2023 and held it in 7 quarters. The position peaked at $678K in Q4 2025. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

EntryPoint Capital reported no remaining Pacira BioSciences position as of Q2 2026 after selling out during the quarter.
EntryPoint Capital sold 21,268 Pacira BioSciences shares in Q2 2026, an estimated $481K.
EntryPoint Capital first reported a position in Pacira BioSciences in Q4 2023 and held it in 7 quarters.
EntryPoint Capital's Pacira BioSciences position peaked at $678K in Q4 2025.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.